LIR Life Engages Neuland Labs to Advance Development of Cell Penetrating Peptides for Transdermal GLP-1/GIP Platform

Executive Summary

• LIR Life Sciences entered into a services agreement with Neuland Laboratories Limited to develop and test novel cell‑penetrating peptides (CPPs) for its transdermal GLP‑1/GIP platform.
• The Phase 1 portion of the collaboration is budgeted at US$230,000, with potential expansion into additional phases subject to mutual agreement.
• LIR also engaged Fairfax Partners Inc. for a three‑month digital marketing program costing USD $150,000 to promote its pipeline and corporate story.

Key Details

• Agreement Partner: Neuland Laboratories Limited – a global CDMO with cGMP peptide facilities and FDA/other regulatory approvals.
• Scope of Phase 1: Development and testing of novel CPPs for formulation work and PK/PD studies; future phases contingent on agreed commercial terms.
• Phase 1 Budget: US$230,000 (adjustable based on material quantities produced).
• Strategic Rationale: Enhances pre‑clinical evaluation of LIR’s transdermal GLP‑1/GIP platform and positions the CPP technology for further collaboration and potential clinical development.
• Digital Marketing Engagement: Fairfax Partners Inc. hired for a three‑month “Fairfax+” program; total budget USD $150,000 covering multi‑channel digital advertising, influencer marketing, media placements, and performance reporting.
• CEO Quote: “Retaining Neuland Labs to perform key initial research and development activities allows us to advance our CPP platform with the precision and consistency needed for early development,” said Edward Mills, CEO.

Notable Quotes

• “Retaining Neuland Labs to perform key initial research and development activities allows us to advance our CPP platform with the precision and consistency needed for early development,” – Edward Mills, Chief Executive Officer, LIR Life Sciences.